Drug Delivery Opportunities in Esophageal Cancer: Current Treatments and Future Prospects
Molecular Pharmaceutics · 01.07.2024 · 21 (7) · 3103-3120
DOI: 10.1021/acs.molpharmaceut.4c00246 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, online erschienen am 18.06.2024. Verfasst von Robert C Sabatelle und 3 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Biomedical Engineering and Chemistry, Boston University, Boston, Massachusetts 02215, United States. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Drug Delivery Systems. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 287 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIBIB NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
With one of the highest mortality rates of all malignancies, the 5-year survival rate for esophageal cancer is under 20%. Depending on the stage and extent of the disease, the current standard of care treatment paradigm includes chemotherapy or chemoradiotherapy followed by surgical esophagogastrectomy, with consideration for adjuvant immunotherapy for residual disease. This regimen has high morbidity, due to anatomic changes inherent in surgery, the acuity of surgical complications, and off-target effects of systemic chemotherapy and immunotherapy. We begin with a review of current treatments, then discuss new and emerging targets for therapies and advanced drug delivery systems. Recent and ongoing preclinical and early clinical studies are evaluating traditional tumor targets (e.g., human epidermal growth factor receptor 2), as well as promising new targets such as Yes-associated protein 1 or mammalian target of rapamycin to develop new treatments for this disease. Due the function and location of the esophagus, opportunities also exist to pair these treatments with a drug delivery strategy to increase tumor targeting, bioavailability, and intratumor concentrations, with the two most common delivery platforms being stents and nanoparticles. Finally, early results with antibody drug conjugates and chimeric antigenic receptor T cells show promise as upcoming therapies. This review discusses these innovations in therapeutics and drug delivery in the context of their successes and failures, with the goal of identifying those solutions that demonstrate the most promise to shift the paradigm in treating this deadly disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Biomedical Engineering and Chemistry, Boston University, Boston, Massachusetts 02215, United States.
- Division of Thoracic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114, United States.
ORCID-Profile: Mark W Grinstaff
Förderung
- NCI NIH HHS
- NIBIB NIH HHS
- NCATS NIH HHS
- National Institutes of Health
Zitieren
APA
Sabatelle, R. C., Colson, Y. L., Sachdeva, U., & Grinstaff, M. W. (2024). Drug Delivery Opportunities in Esophageal Cancer: Current Treatments and Future Prospects. Molecular Pharmaceutics, 21(7), 3103-3120. https://doi.org/10.1021/acs.molpharmaceut.4c00246
Vancouver
Sabatelle RC, Colson YL, Sachdeva U, Grinstaff MW. Drug Delivery Opportunities in Esophageal Cancer: Current Treatments and Future Prospects. Molecular Pharmaceutics. 2024;21(7):3103-3120. doi:10.1021/acs.molpharmaceut.4c00246
BibTeX
@article{Sabatelle2024,
author = {Sabatelle, Robert C and Colson, Yolonda L and Sachdeva, Uma and Grinstaff, Mark W},
title = {Drug Delivery Opportunities in Esophageal Cancer: Current Treatments and Future Prospects},
journal = {Molecular Pharmaceutics},
year = {2024},
volume = {21},
number = {7},
pages = {3103--3120},
doi = {10.1021/acs.molpharmaceut.4c00246}
}
EUVIMED